$4.71
0.21% yesterday
Nasdaq, Oct 15, 10:00 pm CET
ISIN
US30049G1040
Symbol
EVOK

Evoke Pharma, Inc. Stock price

$4.71
-0.36 7.10% 1M
+2.61 124.29% 6M
+0.29 6.56% YTD
-0.40 7.83% 1Y
-17.97 79.23% 3Y
-672.09 99.30% 5Y
-584.25 99.20% 10Y
-1,685.85 99.72% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
-0.01 0.21%
ISIN
US30049G1040
Symbol
EVOK
Industry

Key metrics

Basic
Market capitalization
$7.3m
Enterprise Value
$280.0k
Net debt
positive
Cash
$12.1m
Shares outstanding
1.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.6 | 0.5
EV/Sales
0.0 | 0.0
EV/FCF
negative
P/B
1.7
Financial Health
Equity Ratio
40.2%
Return on Equity
-76.1%
ROCE
-120.3%
ROIC
-
Debt/Equity
1.1
Financials (TTM | estimate)
Revenue
$12.8m | $16.1m
EBITDA
- | -
EBIT
$-5.3m | $-5.0m
Net Income
$-5.4m | $-3.0m
Free Cash Flow
$-3.6m
Growth (TTM | estimate)
Revenue
70.1% | 57.4%
EBITDA
- | -
EBIT
14.0% | 3.3%
Net Income
17.5% | 44.3%
Free Cash Flow
34.8%
Margin (TTM | estimate)
Gross
96.6%
EBITDA
- | -
EBIT
-41.7%
Net
-42.1% | -18.5%
Free Cash Flow
-28.3%
More
EPS
$-2.1
FCF per Share
$-2.4
Short interest
3.1%
Employees
3
Rev per Employee
$3.4m
Show more

Is Evoke Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Evoke Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Evoke Pharma, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Evoke Pharma, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Evoke Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
13 13
70% 70%
100%
- Direct Costs 0.43 0.43
95% 95%
3%
12 12
69% 69%
97%
- Selling and Administrative Expenses 18 18
31% 31%
138%
- Research and Development Expense 0.06 0.06
100% 100%
0%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.34 -5.34
14% 14%
-42%
Net Profit -5.38 -5.38
17% 17%
-42%

In millions USD.

Don't miss a Thing! We will send you all news about Evoke Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evoke Pharma, Inc. Stock News

Negative
Proactive Investors
3 days ago
William Hill owner Evoke PLC (LSE:EVOK) has joined Ladbrokes owner Entain PLC (LSE:ENT) in threatening to close hundreds of betting shops if November's Budget brings new taxes on the industry.  The government says it is consulting on introducing new online betting taxes, bringing this more in line with taxes imposed in betting shops.
Neutral
Business Wire
13 days ago
LOS ANGELES--(BUSINESS WIRE)--Ranking recognizes Evoke's achievement in advancing client experience, and its leadership as a trusted advisor in the RIA industry.
Neutral
Business Wire
about 2 months ago
CLEVELAND & LOS ANGELES--(BUSINESS WIRE)--MAI Capital Management strategically partners with Evoke Advisors. Together, the firm will manage approximately $60 billion across over 30 offices.
More Evoke Pharma, Inc. News

Company Profile

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Head office United States
CEO Matthew D'Onofrio
Employees 3
Founded 2007
Website evokepharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today